Literature DB >> 2280609

Oestrogen receptor (ER) analysis in B-cell chronic lymphocytic leukemia: correlation of biochemical and immunocytochemical methods.

N Melo1, C Hobday, M Dowsett, D Catovsky, E Matutes, R Morilla, A Polliack.   

Abstract

Oestrogen receptors (ER) are present in neoplastic lymphoid cells and have been considered a physiological marker of growth rate or differentiation. Tamoxifen, an oestrogen antagonist, has been given in some patients with CLL and Hodgkin's disease, with dramatic response in single cases. Until now, ER status has been assessed using a steroid binding assay (SBA) which has many inherent problems. Recently, the development of monoclonal antibodies directed against ER has been applied to the study of breast carcinomas and results obtained show good correlation with the quantitative SBA. We studied 49 cases of B-cell chronic lymphocytic leukemia (CLL) using immunostaining of cytospin preparations. In 30 of these cases ER enzyme immunoassay (ER-EIA) was also performed. Cultured MCF-7 cells, derived from a pleural effusion of a breast cancer patient, known to contain high levels of ER were used as a positive control (40-48% ER positive cells by immunocytochemistry; 200 fmol/mg protein by EIA). All of the CLL cases except two (96%) were negative for ER (less than 1% staining; less than 4 fmol/mg protein). The two positive cases expressed granular ER staining over the nucleus (9.2 and 12.1% positive cells) and were positive by EIA and SBA. It is concluded that (i) patients with CLL rarely express ER and (ii) immunocytochemical staining of cytospin preparations is a valid technique for the measurement of ER. It is of interest that one of the positive cases was diagnosed as CLL with Richter's transformation confirming earlier findings.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2280609     DOI: 10.1016/0145-2126(90)90106-j

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

1.  Possible effect of medroxyprogesterone acetate (MPA) in lymphoid blast crisis of chronic myelogenous leukemia.

Authors:  M Fink
Journal:  Ann Hematol       Date:  1994-02       Impact factor: 3.673

2.  Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study.

Authors:  J A Royle; P D Baade; D Joske; J Girschik; L Fritschi
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

3.  Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients.

Authors:  Eric P Allain; Karin Venzl; Patrick Caron; Véronique Turcotte; David Simonyan; Michaela Gruber; Trang Le; Eric Lévesque; Chantal Guillemette; Katrina Vanura
Journal:  Ann Hematol       Date:  2018-05-21       Impact factor: 3.673

Review 4.  Second neoplasms in patients with chronic lymphocytic leukemia.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2004-06

Review 5.  Aberrant Wnt Signaling in Leukemia.

Authors:  Frank J T Staal; Farbod Famili; Laura Garcia Perez; Karin Pike-Overzet
Journal:  Cancers (Basel)       Date:  2016-08-26       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.